“BP is fully aware of CYDY, LL, and especially Nader. They have passed”
Are you sure about this? My sources tell me different. They have not passed, it’s just a situation where it’s not possible to do a deal right now.
BP wants to pay the valuation for a drug for the singular purpose they want it for. CYDY has no interest in selling unless the valuation is for multiple indications. If this scenario is true, it’s not they they have passed, it’s a matter of valuation.
Just my personal opinion but I would not sell out for a single indication valuation either at this point. Like CYDY, I would want to know what LL is fully capable of first.